---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-091217"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:53:57.711959+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics appoints Dr. Julia A. Haller to board, increases size to 10

## Summary
- Board expanded from 9 to 10 members; Dr. Haller appointed as Class II director effective Aug 11, 2022.
- Dr. Haller replaces Randy Thurman on Nominating and Corporate Governance Committee; Thurman stays on board.
- Received option for 25,000 shares at $1.15 (Aug 11 close), vesting over 3 years under 2015 Equity Incentive Plan.
- Standard indemnification agreement entered; compensation per non-employee director policy.

## SEC filing metadata
- accession: 0001104659-22-091217
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465922091217/0001104659-22-091217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465922091217/tm2223402d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-091217
- JSON: https://secwatch.observer/filing/0001104659-22-091217.json
- Plain text: https://secwatch.observer/filing/0001104659-22-091217.txt

## Key facts
- Executive change
  Julia A. Haller was appointed as Director at Outlook Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Dr. Julia A. Haller to fill the newly created vacancy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465922091217/0001104659-22-091217-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.